Evaluating Interleukin 6 Versus Procalcitonin to Detect Sepsis and Mortality in ICU Patients with Moderate to Severe Burns

What this Trial Is About

Researchers are evaluating whether Interleukin-6 IL-6 is a better indicator than procalcitonin for detecting sepsis or septic shock in burn patients. The study focuses on patients admitted to the burn intensive care unit ICU with acute burns, aiming to assess treatment success and early ICU discharge. This research is sponsored by Ain Shams University and involves adult patients between 25 and 60 years old with moderate burns. All participants will have blood samples taken to measure IL-6 and procalcitonin levels on days 1, 3, 7, and 10 after ICU admission. Treatment will follow the standard burn ICU protocol, and the levels of IL-6 and procalcitonin will guide clinical decisions about patient improvement and ICU stays. The study does not use blinding or placebo controls. Participants will be monitored for signs of sepsis and septic shock from day 1 to day 10 in the burn ICU. Researchers will also track the length of ICU stay for up to one month after admission. The study includes regular lab testing and clinical assessments to measure outcomes and guide treatment. The total participation time will vary based on ICU stay and follow-up care.

Comparison Between Interleukin 6 and Procalcitonin in Detecting Sepsis and Incidence of Mortality in Burn ICU Patients